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Collectively, rare diseases represent a significant public health burden for both affected 
families and health and social care services.  Rare diseases should be a key priority for 
healthcare providers within Northern Ireland.  A rare disease is defined by the European 
Union as one that affects less than 5 in 10,000 of the general population with ~8,000 rare 
diseases recorded.  1/17 individuals are affected by a rare disease, which equates to more than 
100,000 individuals (a similar number to the population of Derry/Londonderry) in Northern 
Ireland. Individuals, carers and families who are affected by rare disease are protected by 
equality legislation and human rights standards, and are therefore entitled to the same level of 
care and support as those who are affected by more common conditions. In essence what this 
means is that patients with a rare disease (and their families) expect to have access to services 
provided by professionals who understand their condition and have access to the appropriate 
medical tools and devices to manage their condition effectively. 
 
It is not feasible for the Northern Ireland health service to provide “in house” experts for all 
rare diseases. Northern Ireland has a relatively small population and as a result, for many rare 
disease, we do not have the critical mass of affected individuals to allow clinicians to develop 
the expertise that would allow them to satisfactorily manage their care.  The provision of a 
local specialist service for very small numbers of patients for all individual rare diseases is not 
economically viable.   
 
Nonetheless, the present care of patients with rare diseases is not as efficient or streamlined as 
possible.  The waste of misdirected NHS resources is immense.  The Northern Ireland Rare 
Disease Partnership (NIRDP) considers that the issues involved - of needless human suffering 
and of waste of public money - demand that workable solutions are found.  Ideally we envisage 
the CERDNI as a productive, collaborative endeavour as we have already established strong 
academic - clinical - government – industrial - voluntary sector links through evaluating the 
logistics of how a NI centre of expertise for rare diseases could be most effective.  This 
represents an innovative solution to the challenges of improving the plan for rare disease, 
reducing expenditure on referrals outside NI, and improving quality of service and outcomes 
for those with rare disease, might be to work towards the establishment of a Northern Ireland 
Rare Disease “Centre of Expertise”.  We believe that NI already has a range of experts with 
relevant expertise and is ideally suited to the creation of such a centre, which would benefit: 
 
 
 Patients and carers by providing access to standardised information to help them 
understand what to expect with their rare disease (the ‘patient journey’), helpful guides to 
empower those affected, links to relevant support networks and voluntary groups.  Ideally 
this CERDNI will help generate standardised care guidelines to optimise diagnosis, 
treatments and quality of life as well as translating promising research results into 
clinically relevant treatments. 
 
 Clinicians by providing access to accredited standards of care guidelines, linking to 
relevant sources of professional information, and helping generate validated clinical 
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outcome measurements for rare diseases.  Training and education would also be facilitated 
through the expert network of healthcare professionals. 
 
 Healthcare providers by generating (or linking to existing) natural histories aiding 
strategic service planning and commissioning of relevant services 
 
Researchers by contributing to well-designed natural history studies to help understand that 
aetiology and progression of rare diseases.  To help validate relevant clinical outcomes, identify 
biomarkers, aid the development of potential therapies, and recruiting patients to clinical trials. 
The enhanced embedding of research in health service delivery will enable faster uptake of 
evidence-based best care, thereby improving the health of the population affected by a rare 
disease in Northern Ireland.  Industrial partnerships will maximise translational medicine 
through new drug targets, biomarkers and clinical trials/practice.  Rare disease efforts are 
currently supported by international pharmaceutical partners and Northern Ireland has a 
significant and growing pharmaceutical, diagnostic and biotechnology industry that offers NI 
substantial potential to prepare us for the future challenges of rare disease research and service 
delivery.   
 
We are keen that CERDNI is of maximum benefit to individuals in NI living with a rare 
disease, as well as the professional clinicians, support team, commissioners and policy 
makers.  Ideally there would be an advisory group comprising active stakeholders to 
ensure a long-term, sustainable resource that meets the needs of individuals living in 
Northern Ireland.  The School of Medicine, Dentistry and Biomedical Sciences at Queen’s 
University has invested more than £90 million in research infrastructure, buildings, equipment 
and facilities, with a further £85 million expenditure anticipated over the course of the next 
five years, to create a world class Institute of Health Sciences and Health Sciences Campus.  
The University of Ulster has recently established a new £11.5M Northern Ireland Centre for 
Stratified (Personalised) Medicine and is committed to its development as an area of 
excellence. We envisage five essential components of CERDNI including: 
 
1. Multidisciplinary Clinics:  Rare disease networks and multidisciplinary teams are often 
vital to improve patient’s lives.  The communications infrastructure and network of 
professionals (including expert patients) resourced by a comprehensive multidisciplinary 
clinical cannot be underestimated.  As an excellent European example of good practice, the 
Treat-NMD network for neuromuscular diseases (http://www.treat-nmd.eu) was 
established in 2007 and now has 22 interested partners covering 11 countries with more 
than 300 collaborators worldwide.  
 
In Northern Ireland, there have been recent developments for patients affected by 
Neuromuscular diseases, including the development of a patient journey that has a commitment 
to be piloted by all Trusts in the local commissioning plan 2013/2014.  The South West of 
England Neuromuscular Network has demonstrated the improvements that can be made to 
specialist care if services are linked together in an effective and efficient way. The Network is 
overseen by a group of NHS, patient representatives and health professionals such as 
Neuromuscular Care Advisors to help co-ordinate service provision for patients with complex 
neuromuscular conditions and their families.  Specialist care and support must to be provided 
at the right times throughout the lives of patients.  This includes during the period of diagnosis 
and throughout the progression of rare conditions, when proper management is 
required.  ‘Anticipatory care’ - planning ahead when it comes to thinking about specialist 
equipment and other interventions – is vital not only to improve lives, but to reduce costs as 
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well.  There is a clear cut financial argument for this proactive approach – a recent NHS audit 
found 40 percent of the emergency admissions to hospital for neuromuscular patients could 
have been prevented through appropriate care.  Multidisciplinary teams at ‘Centres of 
Excellence’ for muscular dystrophy and related conditions, such as Newcastle’s Centre for 
Life, Great Ormond Street Children’s Hospital in London and the John Radcliffe in Oxford, 
are well prepared for this approach.  At such Centres, families can access specialist support 
from expert consultants and health professionals, which may include diagnostics, ongoing 
physiotherapy and integrated cardiac and respiratory services.  By establishing links with 
community based teams through a formal network; additional health professionals can gain 
skills with more in depth knowledge of very rare conditions.        
 
A multidisciplinary model has already proven successful for some rare diseases in Northern 
Ireland.  Additionally, a specialist multidisciplinary clinic runs for patients affected by Fabry 
disease in NI to the same management guidelines as specialist centres in England.  For some 
individuals affected by some other lysosomal storage disorders, expert consultants travel to 
Northern Ireland, while other patients attend designated centres in England.  Patients referred 
to an expert centre outside Northern Ireland will often need to be accompanied by a carer, 
family member or friend; thus increasing the cost of such trips.  It is also important to realise 
that individuals with a rare disease are only one part of their family.  Families will often have 
other children and will have commitments close to home that make travelling to and from 
specialist centres very difficult.  Coordinated care between specialist centres and local services: 
individuals affected by a rare disease may receive their specialist care outside of Northern 
Ireland but they are much more likely to develop complications, have accidents that require 
A&E visits, and pick up minor illnesses when they are at home; it is essential that local teams 
develop close links with specialist centres.    
 
The opportunity to avail of such expert specialist knowledge should be equitably available to 
all individuals in NI living with a rare condition by in person visits, travel to expert centres 
(although some individuals may not be well enough to travel) or interactive telemedicine links. 
 
 
2. Improved Diagnosis and Patient Journey.  
Early interventions substantially improve the quality and life expectancy for affected 
individuals, but a recent survey showed ~30% of individuals waited 1-5 years for an accurate 
diagnosis with some individuals waiting more than ten years.  Many individuals see more than 
10 doctors and UK studies suggest that up to 40% of costs could be saved with improved 
preventative care minimising the number of unplanned hospital admissions.  At least 80 per 
cent of rare diseases have a genetic origin. 
 
Northern Ireland has a single regional genetics centre through which all tests are processed.  
This centre has integrated clinical diagnostics, geneticists and NHS-QUB research staff for 
more than 40 years.  The national plan for rare diseases places a strong focus on genetics and 
technological advantages mean that many current ‘common’ conditions are being separated 
into many subtypes.  The decreasing costs of next generation sequencing are enabling 
transformative approaches for rare disease research and NI is ideally suited to conduct a range 
of research projects with standardised, automated comprehensive next generation sequencing 
as well as improving quality control and effective verification of novel markers that may 
contribute to diagnostic pathways.  Several publications support the use of next generation 
diagnostics for cost-effective diagnostic use, resources such as Addenbrookes hospital are 
developing a number of next generation sequencing services that will soon be offered for 
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clinical diagnostic use 
(http://www.cuh.org.uk/addenbrookes/services/clinical/genetics/genetics_labs/news/next_gen
eration_sequencing.html) and the UK genetic testing network has evaluated several panels that 
minimise clinicians wasting time and delayed patient diagnosis by having to order each single 
test sequentially.  The developments of these tests not only improve patient’s experience of 
diagnosis, but often inform on the disease course, minimise invasive tests, and save costs!  A 
case study of glycogen storage disorder using a targeted next generation sequencing approach 
enables a saving of £237,405 per annum and leads to definitive diagnostic testing based on the 
expected number of 70 referrals per annum for the UK population (Dr Shehla Mohammed, 
Clinical Advisor, UK Genetic Testing Network, which advises the NHS on genetic testing 
across the UK, in the 3rd Annual report, Nov 2012). 
 
Northern Ireland’s Centre for Public Health (QUB) and the Regional Genetics Centre (BHSCT) 
already acts as the European centre for multiple genetic and epigenetic studies for a range of 
diseases with extensive experience storing and analysing complex biological samples, 
including next generation sequencing and clinical bioinformatics. 
 
For rare diseases without a genetic cause, the process of diagnosis may also be challenging due 
to infections, allergies, degenerative causes etc.  Often patients will have multiple 
complications, see many consultants and attend lots of different clinics on different days.  
Where possible, care should be coordinated into a ‘multi-stop-clinic’ attended by a 
multidisciplinary team that will maximise patient attendance, facilitate cross-disciplinary 
expertise and minimise patients having inappropriate care.  The development of patient 
journeys that help each patient understand what to expect at key stages of their disease 
progression will help minimise patient anxiety and empower affected individuals to make 
informed choices about their care and lifestyles. 
 
 
3. Clinical Trials and Orphan Drugs.  It is vitally important that local individuals are able 
to access clinical trials and funding for orphan drugs as other patients in the UK.  Improved 
professional support is also required to facilitate local individuals participating in clinical 
trials; at present some individuals in NI cannot contribute to clinical trials as they do not 
have sufficient follow-up care through routine appointments.  This is particularly 
disappointing given the development of the new Wellcome Trust-Wolfson Northern 
Ireland Clinical Research Facility, the NI Cancer Trials Centre, and the Medical Research 
Council Methodology Hub.  Established links with pharmaceutical companies would 
enhance the research and translational hub and potentially benefit the economy. 
 
 
4. Streamlined cross-border commissioning facilitating access to relevant international 
specialist centres for rare diseases: At present, some individuals from NI are waiting 
prolonged periods of time to access specialist care for their conditions in Europe.  Once 
approved, difficulties are still experienced on arrival at their specialist centre and the 
existing language barriers that cause difficulties accessing care and translating medical 
notes need resolved.  
 
5. Information Hub: A dedicated information hub for rare diseases is a powerful tool for 
surveillance, epidemiology, service planning, and would minimise costs, facilitate delivery 
of the national plan, and maximise Northern Ireland’s ability to contribute to leading 
research for rare diseases.  The development of this information hub would standardise data 
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collection and storage with a single entry point for access, maintain agreed core information 
sets for rare diseases in line with European policy, enable efficient accurate data validation, 
active updating, routine auditing, and integration with international registries.  This would 
also minimise organisational / IT complexities integrating multiple information structures, 
and ensure compliance with data protection, quality assurance, governance and standardise 
legal issues including acting as a ‘consent’ centre for patient participation and the central 
portal for relevant clinical trials.  Ideally primary data would be automatically derived from 
electronic healthcare records with extensive curation and validation, as well as having the 
facility to allow collection of data directly reported by patients and healthcare 
professionals.  Such collation of data would also ensure that relevant medical information 
(patient history, disease information guidelines and contact details for further information) 
is available in a timely and appropriate manner when a patient with a rare disease presents 
at A&E in crisis.  NI’s electronic care record has already proved transformational and it is 
possible that a ‘front page’ of key/critical information would maximise patient outcomes 
during acute hospital admissions; we understand this ‘alert’ system for the ECR may be 
operational within 6 months.  CERDNI would also enable the integration of resources such 
as a rare disease clinical registry with research-based next generation sequencing, 
metabolomic, proteomic and imaging data to improve clinical risk provision by identifying 
biomarkers for disease and optimising treatment. 
 
An example of a UK-wide resource:  The UK renal community has collectively contributed to 
the establishment of a Renal Registry (www.renalreg.com) that brings together rich clinical 
data under a careful confidentiality and governance framework; there is 100% participation 
from renal units across the UK and the 16th annual report is being generated.  Patients are 
provided with access to up-to-date data for their medical condition via renal patient view 
(www.renalpatientview.org) and are thus able to contribute and share important information 
with relevant professionals anywhere in the world. This resource provides informative, 
standardised and validated data for comparative analyses, quality assurance, auditing, service 
planning, clinical governance and research for participating units, NHS Trusts, and 
commissioning authorities.  Specific to rare renal diseases is a dedicated developing website 
(rarerenal.org) that provides information for clinicians, information for patients and their carers 
in accordance with the Information Standard, as well as providing information on National 
Studies of Rare Kidney Diseases. The latter includes the national patient registry renal_RaDaR 
that serves patients with over 25 rare conditions.  This resource also provides the opportunity 
for epidemiological surveillance and identifies patients with rare renal diseases who may 
benefit from / contribute to clinical trials.  Nationally approved expert rare renal disease groups 
provide detailed information and advice on tests, treatment and research; these groups must 
fulfil clear objectives to maintain approval by the professional organisation the Renal 
Association (www.renal.org), and contain patient representation as well as worldwide expertise 
from disciplines outside renal medicine.   
 
a. Registries:  Due to the rarity of patients and the scarcity of information related to 
individual rare diseases, collaborative endeavours are necessary, indeed the EU 
Council Recommendation on Rare Diseases and the EU Parliament and Council 
Directive on Cross-Border Health Care emphasises the need and urgency for 
cooperation among Countries in collecting and sharing data to foster research and 
care regarding patients living with rare diseases.  This information should be used 
to support policy development, facilitate clinical and epidemiological research, 
therapeutic monitoring and evaluation of on/off label approved drug use, as well as 
facilitating clinical trials. 
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Northern Ireland currently coordinates the central registry for a network of population-based 
resources for congenital anomalies (www.eurocat-network.eu/), despite NI not contributing 
data from affected individuals directly.  This established network uses a standardised protocol 
to collect data, surveying more than 1.7 million births per year in Europe, with 43 registries in 
23 countries at European level. The EUROCAT Coding and Classification Committee  are also 
currently liaising  with the WHO, Orphanet and EURCERD in the revision of the 
Developmental Anomalies chapter of the new ICD 11 to develop to coding of congenital 
anomalies and other Rare Diseases.  EUROCAT have also developed recommendations on 
policies to be considered for the primary prevention of congenital anomalies in National Plans 
(and strategies) on Rare Diseases. (http://www.eurocat-network.eu/content/EUROCAT-
EUROPLAN-Primary-Preventions-Recommendations.pdf).   
 
Northern Ireland also hosts many other successful resources, including the Cancer Registry 
(http://www.qub.ac.uk/research-centres/nicr/), cerebral palsy register 
(http://www.qub.ac.uk/research-centres/nicpr), Northern Ireland Childhood Diabetes Register, 
the European collaboration of childhood diabetes registers is co-ordinated from NI 
(EURODIAB, established 1989), the current chair of the UK Renal Registry is based in 
Northern Ireland (www.renalreg.com), a database of all individuals receiving a kidney 
transplant with up to 40+ years of comprehensive follow-up data, several long-term followup 
studies most recently NICOLA (Northern Ireland COhort for the Longitudinal study of Aging), 
and the Northern Ireland Barrett’s Oesophagus Register has resulted in changes to clinical 
practice that minimise costs to healthcare providers and patients. 
 
To be of maximum value to individuals and their families, health and social care providers, 
and local policy makers it is important that a regional population based registry of rare diseases 
in Northern Ireland is developed. Such a population based registry is essential for Northern 
Ireland and is timely with the recommendations on Rare Diseases Registry’s and Data 





b. Web-based portals for disseminating information to patients and healthcare 
professionals.   
 
Due to the nature of rare diseases there are also very significant issues relating to both missed-
diagnosis and misdiagnosis.  There is an urgent need to improve awareness and educate 
medical professionals by providing ‘diagnostic signposts’ to ensure that service providers at 
primary and secondary care level are educated to consider the possibility of rare disease.  It is 
also essential that medical professionals know how to appropriately refer patients for ongoing 
care.  For many conditions it is possible to carry out initial tests locally. If initial test are carried 
out locally this can cut down the costs associated with potentially inappropriate referrals to 
recognised specialist centres outside Northern Ireland.    This online resource could facilitate a 
“Virtual Clinical Team” led by clinicians across medical specialities, associated healthcare 
professionals, service providers.  The web-based portal would enable access to appropriate, 
updated information from Centres of Excellence for all rare diseases, by forming the nucleus 
of a networking system: assimilating high quality advice, improving diagnostics and 
coordination of care.  This resource would provide a network of support for local professionals 
and empower those professionals to manage a small number of patients with rare disease(s). 
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We believe the creation of the NIRDP and the generation of this draft plan with community 
stakeholders shows the dedication and commitment of a diverse range of individuals in 
Northern Ireland to ensure Northern Ireland is well placed to capitalise on rare disease 
developments.  Our unique distribution of services and datasets, including a combined Health 
and Personal Social Services, central population-wide collation of electronic prescriptions 
[EPD the Enhanced Prescribing Database] and the inclusion of the Health and Care Number 
(HCN) as a unique identifier in healthcare datasets, offers unparalleled potential for fully 
integrated population based research in Northern Ireland.  The collation of datasets in a central 
data warehouse accessed via the honest broker initiative facilitates the safe linkage of sensitive 
datasets and supports the analysis of datasets within secure / ‘safe haven’ locations.  Making 
better use of information to help planning and delivering of healthcare for individuals affected 
by rare diseases is a critical development for Northern Ireland in particular.  The launch of the 
Northern Ireland Electronic Health Record and the focus on personalised medicine in within 
the Transforming Your Care process, as well as the development of UK and NI implementation 
plan for rare disease make this a particularly timely endeavour.  Health Minister Poots & 
Minister White (Primary Care at the DOH, ROI) both spoke at local rare disease conferences 
earlier this year, as did vice presidents from EURODIS, EU Committee of Experts on Rare 
Diseases, and John Rowan from the European Commission, Healthcare Systems Unit, SANCO 
D2.   
 
This report recommends Northern Ireland develops a collaborative Centre of Expertise 
for Rare Disease (CERDNI), incorporating genetic diagnostics, a rare disease registry / 
electronic linkage of health records, and implementing the NIRD plan with evidence-
based commissioning and translational research that changes lives.  
 
